MDVN : Analysis & Opinions

  1. Bull of the Day: Endocyte (ECYT) - Bull of the Day

    February 12, 2014
    Bull of the Day: Endocyte (ECYT) - Bull of the Day
  2. Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook

    December 3, 2013
    Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook
  3. Pharma & Biotech Stock Outlook - July/Aug 2013 - Industry Outlook

    July 30, 2013
    Pharma & Biotech Stock Outlook - July/Aug 2013 - Industry Outlook
  4. Astellas Launches Xtandi in the UK - Analyst Blog

    July 12, 2013
    Astellas Pharma announced the launch of its prostate cancer drug, Xtandi, in the UK
  5. Patient Enrolled in Medivation Study - Analyst Blog

    June 28, 2013
    Xtandi is being evaluated in several studies including a phase II breast cancer study.
  6. Alexion 4Q Tops on Both Lines - Analyst Blog

    February 14, 2013
    Alexion Pharmaceuticals Inc.'s (ALXN) fourth quarter 2012 earnings (excluding special items but including stock-based compensation ...
  7. Priority FDA Review for Celgene Drug - Analyst Blog

    February 12, 2013
    Recently, Celgene Corporation (CELG) announced that the US Food and Drug Administration (FDA) will review the supplemental ...
  8. Gilead Closes YM Biosciences Buyout - Analyst Blog

    February 11, 2013
    Recently, Gilead Sciences, Inc. (GILD) completed its acquisition of Canada-based drug development company, YM BioSciences ...
  9. Medivation's Xtandi Impresses - Analyst Blog

    February 7, 2013
    Medivation, Inc. (MDVN) recently announced that its partner Astellas Pharma Inc. (ALPMY) reported Xtandi (enzalutamide) sales ...
  10. Kalydeco Funding Cleared in Ireland - Analyst Blog

    February 6, 2013
    Vertex Pharmaceuticals Inc. (VRTX) recently announced that the Health Service Executive (HSE) in the Republic of Ireland ...
  11. Gilead Beats Estimates in 4Q - Analyst Blog

    February 5, 2013
    Gilead Sciences, Inc.'s (GILD) fourth quarter 2012 earnings (excluding special items but including stock option expense) ...
  12. US Nod for ISIS/Sanofi's Kynamro - Analyst Blog

    January 30, 2013
    The US Food and Drug Administration (FDA) recently approved Kynamro (mipomersen sodium) injection developed by Genzyme, a ...
  13. 4Q Revenues Decline at Vertex - Analyst Blog

    January 30, 2013
    Vertex Pharmaceuticals Inc. (VRTX) posted a loss of 9 cents per share (including stock-based compensation expense) in the ...
  14. Biogen Advances with MS Candidate - Analyst Blog

    January 25, 2013
    Biogen Idec (BIIB) recently announced positive top-line data on its phase III multiple sclerosis candidate, peginterferon ...
  15. Biogen Idec and More Big Movers in Healthcare on January 3, 2 ...

    January 3, 2013
    This morning, the market has been relatively quiet. The Nasdaq remains relatively unchanged; the S&P 500 is unchanged; and ...
  16. Regeneron Pharmaceuticals and Other Healthcare Stocks Making ...

    December 27, 2012
    It's been a bad day for the market after the morning's trading. The Nasdaq is down 0.7%; the S&P 500 is trading down 0.8%; ...
  17. Nasdaq Stocks, Including Facebook Inc. - Class, Making Big Moves ...

    December 24, 2012
    The market is having a bad day so far: the Nasdaq is trading down 0.2%; the S&P 500 has declined 0.3%; and the Dow has fallen ...
  18. Medivation and Other Big Movers In Healthcare on December 3, ...

    December 3, 2012
    After the morning's trading, the Nasdaq is up 0.2%, the S&P 500 has declined 0.1% and the Dow is trading down 0.2%. The healthcare ...
  19. Regeneron Pharmaceuticals Among Healthcare's Biggest Movers on ...

    November 15, 2012
    The market is currently down, with the Nasdaq falling 0.4%, the S&P 500 decreasing 0.3% and the Dow declining 0.3%. The healthcare ...
  20. Vertex Pharmaceuticals Among Healthcare's Biggest Movers on November ...

    November 14, 2012
    The market is having a bad day so far. The Nasdaq has decreased 0.4%; the S&P 500 has fallen 0.5%; and the Dow is down 0.7%. ...
  21. Loss at DNDN Wider than Expected - Analyst Blog

    November 6, 2012
    Dendreon Corporation (DNDN) reported third quarter 2012 adjusted loss of 86 cents per share, wider than the Zacks Consensus ...
  22. Is “Less Bad” As Good As It Gets For Dendreon?

    November 5, 2012
    Dendreon has made progress with its expenses, but the sluggish revenue growth is still the major problem.
  23. Vertex Pharmaceuticals and Other Healthcare Stocks Making Big ...

    November 2, 2012
    The Nasdaq remains relatively unchanged, the S&P 500 has decreased 0.2% and the Dow has declined 0.3% after the morning's ...
  24. Dendreon Treads the Neutral Path - Analyst Blog

    October 11, 2012
    We are maintaining our Neutral recommendation on Dendreon Corporation (DNDN) with a target price of $4.75. The stock carries ...
  25. Alexion Pharmaceuticals and Other Big Movers In Healthcare on ...

    October 8, 2012
    The Nasdaq has fallen 1%, the S&P 500 has declined 0.4% and the Dow is trading down 0.3%, marking a bad morning for the market. ...
  26. Teva Acquires Huntington Candidate - Analyst Blog

    October 4, 2012
    Teva Pharmaceutical Industries Ltd (TEVA) recently announced a deal that will expand the company's central nervous system ...
  27. Omnicare Inks Distribution Deal - Analyst Blog

    October 4, 2012
    Advanced Care Scripts (ACS), a part of Omnicare Inc.'s (OCR) Specialty Care Group, has been recently included in the limited ...
  28. Medivation and More Big Movers on the Nasdaq on September 27, ...

    September 27, 2012
    After this morning's trading, the Nasdaq has increased 0.4%, the S&P 500 has moved up 0.3% and the Dow has remained steady. ...
  29. Healthcare Stocks, Including HCA, Making Big Moves on September ...

    September 27, 2012
    After the morning's trading, the Nasdaq has increased 0.4%, the S&P 500 has risen 0.3% and the Dow has moved little. The ...
  30. Baxter and Other Healthcare Stocks Making Big Moves on September ...

    September 26, 2012
    This morning's trading has marked a bad day for the market so far. The Nasdaq has slipped 1%; the S&P 500 has fallen 0.5%; ...
  31. Medivation-Astellas Launch Xtandi - Analyst Blog

    September 17, 2012
    Medivation, Inc. (MDVN) and Astellas Pharma Inc. recently launched their prostate cancer treatment, Xtandi (enzalutamide) ...
  32. Gilead and More Big Movers on the Nasdaq on September 17, 2012

    September 17, 2012
    The market is down this morning. The Nasdaq is down 0.2%; the S&P 500 is trading down 0.2%; and the Dow has slipped 0.2%. ...
  33. Healthcare Stocks, Including Novo Nordisk A/S, Making Big Moves ...

    September 12, 2012
    The morning has been good for the market. The Nasdaq has moved up 0.1%; the S&P 500 has risen 0.3%; and the Dow has increased ...
  34. Medivation's Xtandi Approved - Analyst Blog

    September 4, 2012
    Medivation, Inc. (MDVN) and partner, Astellas Pharma Inc., received a major boost with the US Food and Drug Administration ...
  35. ARM Holdings plc and Other Nasdaq Stocks Making Big Moves on ...

    September 4, 2012
    This morning has been rocky for the market. The Nasdaq has decreased 0.8%; the S&P 500 has slipped 0.5%; and the Dow is down ...
  36. Valeant Pharmaceuticals Int and More Big Movers in Healthcare ...

    September 4, 2012
    The market is currently down, with the Nasdaq slipping 0.8%, the S&P 500 down 0.6% and the Dow declining 0.8%. The healthcare ...
  37. The Week Ahead In Healthcare

    August 8, 2012
    The week ahead for healthcare stocks.
  38. Pfizer & JNJ End Bapineuzumab IV - Analyst Blog

    August 7, 2012
    Pfizer, Inc. (PFE) recently announced disappointing late-stage results on intravenous (IV) bapineuzumab. Bapineuzumab is ...
  39. Dendreon Misses Estimates, Cuts Jobs - Analyst Blog

    July 31, 2012
    Dendreon Corporation (DNDN) reported second-quarter 2012 loss (including stock-based compensation expense but excluding other ...
  40. Big Movers on the Healthcare Sector Today, Including ISRG

    July 30, 2012
    The market is having a bad day so far. The Nasdaq has fallen 0.2%; the S&P 500 has declined 0.1%; and the Dow is trading ...
  41. Healthcare Sector's Biggest Movers for June 29, 2012

    June 29, 2012
    On a good day for the market, the Nasdaq is up 2.4%, the S&P 500 is trading up 1.9% and the Dow has climbed 1.7%. The healthcare ...
  42. Medivation Seeks EU Approval - Analyst Blog

    June 28, 2012
    Medivation, Inc. (MDVN) and partner Astellas Pharma Inc. recently submitted the second marketing application for their prostate ...
  43. Biggest Healthcare Sector Movers for June 25, 2012

    June 25, 2012
    The Nasdaq has declined 2%, the S&P 500 has fallen 1.7% and the Dow has slipped 1.3% on a bad morning for the market. The ...
  44. Biotech Stocks With Bullish Trends From Short Sellers

    March 26, 2012
    One of the clearest sentiment indicators comes from short sellers. Changes in the number of shares shorted over time can ...
  45. The Top Biotech Performers Of 2011

    December 27, 2011
    Investors found huge winners in Hepatitis C and cancer this year.
  46. Dendreon's Chinese Water Torture

    November 3, 2011
    Dendreon's Provenge continues to shape up as a major disappointment.
  47. The Best And Worst Stocks For The Year

    August 2, 2010
    Ten stocks have climbed 200% since New Year’s, while more than 25 have lost over half their value.
  48. 3 Biotech Stocks On The Move

    March 10, 2010
    All three of these biotech companies are swinging for the fences and this approach has been reflected in their stock prices.
  49. A Review Of The Drug Makers Of 2009

    December 29, 2009
    Corporate deal-making was the name of the big pharma game in 2009 and will likely continue into the new year.
  50. High-Risk Acquisition The Right Prescription For Pfizer?

    September 5, 2008
    Pfizer needs to refresh its pipeline, but taking on a high-risk/high-reward experimental drug could do more harm than good.
Investing News
  1. 3 Dumb Ways to Borrow Money

    Money — everyone needs it, but not everyone has it. Many people who find themselves in a ...
  2. Infographic - The Lifecycle of a Bond

    Basic information on how Bonds work.
  3. What $200,000 Will Buy In The Atlanta Real Estate Market

    Atlanta housing prices are up from last year, but they're still lower than the national median. ...
  4. Bubble Bursting? Only For Biotech & Internet Stocks

    The recent sluggish performance of U.S. stocks is leading some market watchers to question ...
  5. What $300,000 Will Buy In The Riverside/San Bernardino Real Estate Market

    The median list price for the San Bernardino/Riverside, Calif. market is $292,800, up 24.6% ...
  6. What Is Worse Than Being At Risk?

    You may have heard the old adage: “What is worse than being lost? Not knowing you are lost.” ...
Trading Center